161 related articles for article (PubMed ID: 18556884)
1. Hereditary breast and ovarian cancers.
Herman LM;
JAAPA; 2008 May; 21(5):18, 21. PubMed ID: 18556884
[No Abstract] [Full Text] [Related]
2. NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer.
Berliner JL; Fay AM; Cummings SA; Burnett B; Tillmanns T
J Genet Couns; 2013 Apr; 22(2):155-63. PubMed ID: 23188549
[TBL] [Abstract][Full Text] [Related]
3. Genetic/familial high-risk assessment: breast and ovarian.
Daly MB; Axilbund JE; Buys S; Crawford B; Farrell CD; Friedman S; Garber JE; Goorha S; Gruber SB; Hampel H; Kaklamani V; Kohlmann W; Kurian A; Litton J; Marcom PK; Nussbaum R; Offit K; Pal T; Pasche B; Pilarski R; Reiser G; Shannon KM; Smith JR; Swisher E; Weitzel JN;
J Natl Compr Canc Netw; 2010 May; 8(5):562-94. PubMed ID: 20495085
[No Abstract] [Full Text] [Related]
4. Pretest genetic counseling informs patients with BRCA mutation.
Printz C
Cancer; 2012 Dec; 118(24):6017. PubMed ID: 23208671
[No Abstract] [Full Text] [Related]
5. One risk fits all?
De Bock GH; Mourits MJ; Oosterwijk JC
J Clin Oncol; 2007 Aug; 25(22):3383-4; author reply 3384. PubMed ID: 17664491
[No Abstract] [Full Text] [Related]
6. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Berry DA; Iversen ES; Gudbjartsson DF; Hiller EH; Garber JE; Peshkin BN; Lerman C; Watson P; Lynch HT; Hilsenbeck SG; Rubinstein WS; Hughes KS; Parmigiani G
J Clin Oncol; 2002 Jun; 20(11):2701-12. PubMed ID: 12039933
[TBL] [Abstract][Full Text] [Related]
7. Questions raised by BRCA1/2-carrier screening programs.
Gilbert F
Genet Test; 2002; 6(2):71-4. PubMed ID: 12229875
[No Abstract] [Full Text] [Related]
8. Genetic/familial high-risk assessment: breast and ovarian.
Daly MB; Axilbund JE; Bryant E; Buys S; Eng C; Friedman S; Esserman LJ; Farrell CD; Ford JM; Garber JE; Jeter JM; Kohlmann W; Lynch PM; Marcom PK; Nabell LM; Offit K; Osarogiagbon RU; Pasche B; Reiser G; Sutphen R; Weitzel JN;
J Natl Compr Canc Netw; 2006 Feb; 4(2):156-76. PubMed ID: 16451772
[No Abstract] [Full Text] [Related]
9. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
[TBL] [Abstract][Full Text] [Related]
10. Is it time for BRCA1/2 mutation screening in the general adult population?: impact of population characteristics.
Palomaki GE
Genet Med; 2015 Jan; 17(1):24-6. PubMed ID: 25375653
[No Abstract] [Full Text] [Related]
11. Lessons learned from genetic testing.
Esserman L; Kaklamani V
JAMA; 2010 Sep; 304(9):1011-2. PubMed ID: 20810382
[No Abstract] [Full Text] [Related]
12. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome.
Shulman LP
Obstet Gynecol Clin North Am; 2010 Mar; 37(1):109-33, Table of Contents. PubMed ID: 20494261
[TBL] [Abstract][Full Text] [Related]
13. ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer syndrome.
Obstet Gynecol; 2009 Apr; 113(4):957-966. PubMed ID: 19305347
[TBL] [Abstract][Full Text] [Related]
14. Familial breast and ovarian cancers.
Arai M; Utsunomiya J; Miki Y
Int J Clin Oncol; 2004 Aug; 9(4):270-82. PubMed ID: 15375703
[TBL] [Abstract][Full Text] [Related]
15. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
[TBL] [Abstract][Full Text] [Related]
16. Testing for hereditary breast and ovarian cancer in the southeastern United States.
Miron A; Schildkraut JM; Rimer BK; Winer EP; Sugg Skinner C; Futreal PA; Culler D; Calingaert B; Clark S; Kelly Marcom P; Iglehart JD
Ann Surg; 2000 May; 231(5):624-34. PubMed ID: 10767783
[TBL] [Abstract][Full Text] [Related]
17. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis.
Lu KH
Fam Cancer; 2008; 7(1):53-8. PubMed ID: 17636427
[TBL] [Abstract][Full Text] [Related]
18. [Possibilities of examination of familial breast cancers and ovarian cancers. Use of molecular-genetic analysis of the BRCA1 gene and the BRCA2 gene].
Backe J; Mulfinger L
Krankenpfl J; 1996 Oct; 34(10):440-5. PubMed ID: 8949022
[No Abstract] [Full Text] [Related]
19. Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families.
Kauff ND; Mitra N; Robson ME; Hurley KE; Chuai S; Goldfrank D; Wadsworth E; Lee J; Cigler T; Borgen PI; Norton L; Barakat RR; Offit K
J Natl Cancer Inst; 2005 Sep; 97(18):1382-4. PubMed ID: 16174860
[TBL] [Abstract][Full Text] [Related]
20. Using genetic analysis to individualize preventive measures for breast and ovarian cancers.
Olopade OI
Nat Clin Pract Oncol; 2006 Apr; 3(4):182-3. PubMed ID: 16596140
[No Abstract] [Full Text] [Related]
[Next] [New Search]
